Rheumatologists may benefit from the decentralized technology that makes cryptocurrency possible: blockchain. According to Anh L. Ngo, MD, MBA, using blockchain in healthcare may increase payment and purchasing efficiency and revolutionize EHR management…
Search results for: hospital
FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review
The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…
Rituximab Receives Label Update for ANCA-Associated Vasculitis
The FDA has approved an update for rituximab’s label, which will include safety and efficacy information for treating ANCA-associated vasculitis…
Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab
In a four-year study, patients with active psoriatic arthritis (PsA) experienced sustained improvement in PsA signs and symptoms on secukinumab…
Pediatric Lupus Outcomes: Researchers Follow Kids into Adulthood
A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…
The Burden of Rheumatic Diseases Among Indigenous People in Latin America Is Disproportionate
Indigenous communities in Latin America lack good healthcare—and often lack any healthcare—for musculoskeletal and rheumatic diseases.1 Global health initiatives tend to focus on infectious disease, despite the increasing rate of chronic diseases. In a survey of 6,155 individuals from eight indigenous communities, conducted by a team of Latin American investigators, the prevalence of these conditions…
Phase 2 Results for Mavrilimumab Are In
Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…
2018 ACR Awards of Distinction & ACR Masters
CHICAGO—At the 2018 ACR/ARHP Annual Meeting in October, the ACR and the ARHP honored distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. You’ll also find the 2018 Masters list. In the next issue,…
Tips for Limiting Missed Appointments
Missed appointments have long been a problem for rheumatology practices. A recent poll from the Medical Group Management Association (MGMA) found no-shows were the single biggest challenge reported by practice leaders, with 44% of respondents citing the issue.1 If a patient does not come to the office when scheduled, it starts a cascade of events…
Case Report: The Hairdresser Who Couldn’t Comb Her Hair
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized by pain and morning stiffness at the neck, shoulders and hip girdle. It can be associated with giant cell arteritis (GCA); in fact, the two disorders may represent a continuum of the same disease process. This case describes a patient who initially refused treatment for PMR…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 318
- Next Page »